Bank of America reiterated their underperform rating on shares of Regeneron Pharmaceuticals (NASDAQ:REGN - Free Report) in a research report sent to investors on Tuesday morning, Marketbeat.com reports. The brokerage currently has a $565.00 price target on the biopharmaceutical company's stock.
REGN has been the subject of several other reports. Truist Financial lowered their target price on Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a "buy" rating for the company in a report on Friday, November 1st. Evercore ISI lowered their target price on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an "outperform" rating for the company in a report on Thursday, October 24th. Royal Bank of Canada lowered their target price on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an "outperform" rating for the company in a report on Friday, November 1st. Morgan Stanley decreased their price objective on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an "overweight" rating for the company in a report on Friday, November 1st. Finally, Citigroup started coverage on Regeneron Pharmaceuticals in a report on Thursday, November 14th. They issued a "neutral" rating and a $895.00 price objective for the company. One research analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, Regeneron Pharmaceuticals has a consensus rating of "Moderate Buy" and an average price target of $1,099.90.
View Our Latest Report on REGN
Regeneron Pharmaceuticals Stock Performance
Shares of NASDAQ:REGN traded down $9.50 during trading on Tuesday, hitting $778.50. 1,298,474 shares of the company traded hands, compared to its average volume of 553,082. The stock has a market capitalization of $85.55 billion, a price-to-earnings ratio of 19.27, a PEG ratio of 3.00 and a beta of 0.08. The business's fifty day moving average is $871.59 and its 200-day moving average is $1,010.52. Regeneron Pharmaceuticals has a one year low of $735.95 and a one year high of $1,211.20. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09.
Institutional Investors Weigh In On Regeneron Pharmaceuticals
Institutional investors and hedge funds have recently modified their holdings of the stock. SteelPeak Wealth LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 173.0% in the second quarter. SteelPeak Wealth LLC now owns 1,092 shares of the biopharmaceutical company's stock valued at $1,148,000 after purchasing an additional 692 shares in the last quarter. Mizuho Securities USA LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 625.5% in the third quarter. Mizuho Securities USA LLC now owns 59,341 shares of the biopharmaceutical company's stock valued at $62,382,000 after purchasing an additional 51,162 shares in the last quarter. Tri Locum Partners LP lifted its holdings in shares of Regeneron Pharmaceuticals by 104.5% in the second quarter. Tri Locum Partners LP now owns 17,516 shares of the biopharmaceutical company's stock valued at $18,410,000 after purchasing an additional 8,949 shares in the last quarter. Simplify Asset Management Inc. lifted its holdings in shares of Regeneron Pharmaceuticals by 50.8% in the third quarter. Simplify Asset Management Inc. now owns 9,591 shares of the biopharmaceutical company's stock valued at $10,082,000 after purchasing an additional 3,231 shares in the last quarter. Finally, Catalytic Wealth RIA LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the third quarter valued at $1,334,000. Institutional investors and hedge funds own 83.31% of the company's stock.
About Regeneron Pharmaceuticals
(
Get Free Report)
Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.
Featured Stories
Before you consider Regeneron Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list.
While Regeneron Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
